Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAKs). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor, AZD1480, both as a single agent and in combination with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Suryani, Santi, Bracken, Lauryn S., Harvey, Richard C., Sia, Keith C.S., Carol, Hernan, Chen, I-Ming, Evans, Kathryn, Dietrich, Philipp A., Roberts, Kathryn G., Kurmasheva, Raushan T., Billups, Catherine A., Mullighan, Charles G., Willman, Cheryl L., Loh, Mignon L., Hunger, Stephen P., Houghton, Peter, Smith, Malcolm A., Lock, Richard B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2014
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326541/
https://ncbi.nlm.nih.gov/pubmed/25504635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0647
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg